Table 7.

Cox Regression Analysis For Cardiac Death And BARC 2 to 5 Bleeding Among Cancer Patients

	Cardiac Death		BARC 2 to 5 Bleeding
	Adjusted HR (95% CI)	p Value	Adjusted HR (95% CI)	p Value
Diagnosis within 1 yr of prior PCI	1.92 (1.10–3.36)	0.022	1.75 (1.03–2.98)	0.040
Ongoing treatment at index PCI	0.91 (0.46–1.79)	0.787	1.00 (0.55–1.80)	0.988
Type of cancer
Bladder	3.75 (1.50–9.39)	0.005	1.16 (0.53–2.56)	0.705
Breast	4.27 (1.39–13.13)	0.011	0.92 (0.37–2.29)	0.856
Gastrointestinal tract	4.10 (1.67–10.06)	0.002	0.72 (0.33–1.57)	0.411
Head/neck	2.75 (0.85–8.85)	0.090	1.38 (0.56–3.41)	0.483
Hematopoietic	3.72 (1.42–9.77)	0.008	1.21 (0.57–2.53)	0.621
Hepatic, biliary, pancreatic	0.81 (0.10–6.81)	0.844	0.96 (0.22–4.30)	0.963
Lung	3.64 (1.30–10.22)	0.014	0.85 (0.31–2.38)	0.762
Others	2.16 (0.60–7.79)	0.241	1.70 (0.65–4.46)	0.282
Prostate	Ref.		Ref.
Renal	2.47 (0.63–9.75)	0.197	1.26 (0.45–3.51)	0.656
Skin	3.26 (1.06–9.99)	0.039	1.16 (0.49–2.72)	0.735
Uterine, ovarian	3.45 (0.63–18.96)	0.154	1.51 (0.39–5.88)	0.551

Of the study patients, 93.7% (1,282 of 1,368) and 93.1% (1,274 of 1,368) were entered into the multivariable model for cardiac death and BARC 2 to 5 bleeding, respectively. Variables entered into multivariable models were as follows: for cardiac death: age, female, cardiogenic shock, left ventricular ejection fraction, myocardial infarction at presentation, chronic kidney disease, peripheral artery disease; for BARC 2 to 5 bleeding: age, female, body mass index, chronic kidney disease, prior bleeding, anemia, any dual antiplatelet therapy, and oral anticoagulant/direct oral anticoagulant at discharge.

Abbreviations as in Table 6.